A Randomized Double-Blind Clinical Study on Modified Runji Ointment in the Treatment of Psoriasis with Blood Dryness Syndrome Based on Chitosan Nanotechnology
- Conditions
- Psoriasis Vulgaris
- Registration Number
- ITMCTR2000003446
- Lead Sponsor
- Beijing Traditional Chinese Medicine Hospital Shunyi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients who meet the diagnostic criteria of Western medicine psoriasis vulgaris;
2. Patients who meet the syndrome differentiation standard of psoriasis blood dryness syndrome;
3. Patients aged from 18 to 65 years old;
4. Severity of disease: the degree of skin lesions is mild to moderate (skin area < 30% of body surface area);
5. The informed consent form was signed and the subjects were volunteers. The informed consent process was in accordance with the provisions of GCP.
1. Pregnant or lactating women with family planning within three months;
2. The patients were treated with vitamin D 3, retinoic acid or corticosteroids within one month;
3. Complicated with cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other serious primary diseases and mental patients;
4. Those who are allergic to the study drug;
5. Patients who are participating in clinical trials of other drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriasis area and severity index;
- Secondary Outcome Measures
Name Time Method visual analogue scale;Dermatology life quality index;Primary Clinical Symptom Index of Traditional Chinese Medicine;